As we recently covered, May 15, 2018, saw the FDA granting approval to Hospira (now a Pfizer subsidiary) for its Retacrit injection, a...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Epogen®
-
-
Today, the FDA announced that it approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen® for the treatment of anemia caused by...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Since our prior article on the litigation between Amgen and Hospira over Hospira’s proposed biosimilar to Amgen’s Epogen®, there have...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
We previously reported that after a public meeting held on May 25, 2017, the FDA’s Oncologic Drug Advisory Committee (ODAC) recommended...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Introduction The Amgen, Inc. and Amgen Manufacturing, Limited (“Amgen”) litigation against Hospira, Inc. (“Hospira”), filed in...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Pfizer announced last week that the FDA’s Oncologic Drug Advisory Committee (ODAC) recommended its proposed biosimilar to Amgen’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]